Fluorescence spectroscopy, ultraviolet-visible absorption spectroscopy, circular dichroism spectroscopy, viscometry, cyclic voltammetry, and differential pulse voltammetry were applied to investigate the competitive interaction of DNA with the three new cycloalkyl α-aminobisphosphonates (D1–D3) and spectroscopic probe, neutral red dye, and Hoechst (HO), in a Tris–hydrogen chloride buffer (pH 7.4). The spectroscopic and voltammetric studies showed that the groove binding mode of interaction is predominant in the solution containing DNA and α-aminobisphosphonates. Furthermore, the results indicated that α-aminobisphosphonate with the lengthy N alkyl chains and larger heterocyclic ring size had a stronger interaction. The principal component analysis and theoretical quantum mechanical and molecular mechanics (QM-DFT B3LYP/6-31+G* and MM-SYBYL) methods were also applied to determine the number of chemical components presented in complexation equilibrium and identify the structure complexes of DNA with the three new cycloalkyl α-aminobisphosphonates (D1–D3), respectively.
Get full access to this article
View all access options for this article.
References
1.
CarterM.T., RodriguezM., and BardA.J. (1989). Voltammetric studies of the interaction of metal chelates with DNA. 2. Tris-chelated complexes of cobalt(III) and iron(II) with 1,10-phenanthroline and 2,2′-bipyridine. J Am Chem Soc, 2, 8901–8911.
2.
ChenM.H., ChenZ., SongB.A., et al. (2009). Synthesis and antiviral activities of chiral thiourea derivatives containing an α-aminophosphonate moiety. J Agric Food Chem, 57, 1383–1388.
3.
CibičkovĽ., HyšplerR., CibičekN., et al. (2009). Alendronate lowers cholesterol synthesis in the central nervous system of rats—a preliminary study. Physiol Res, 58, 455–458.
4.
CibičkovL., PaličkaV., CibičekN., et al. (2007). Differential effects of statins and alendronate on cholinesterases in serum and brain of rats. Physiol Res, 56, 765–770.
5.
ClarkG.R., GrayE.J., and NeidleS. (1996). Isohelicity and phasing in drug-DNA sequence recognition: crystal structure of a Tris (benzimidazole)-oligonucleotide complex. Biochemistry, 35, 13745–13752.
6.
ColemanR.E. (1997). Skeletal complications of malignancy. Cancer, 80, 1588–1594.
7.
ColemanR.E. (2000). Optimising treatment of bone metastases by Aredia (TM) and Zometa (TM). Breast Cancer, 7, 361–369.
8.
ColemanR.E. (2001). Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev, 27, 165–176.
9.
CollinsJ.G., ShieldsT.P., and BartonJ.K. (1994). 1H-NMR of Rh(NH3)4phi3+ bound to d(TGGCCA)2: classical intercalation by a non-classical octahedral metal complex. J Am Chem Soc, 116, 9840–9845.
10.
DannemannC., GrtzK.W., RienerM.O., et al. (2007). Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder. Bone, 40, 828–834.
11.
DasH., WangL., KamathA., et al. (2001). Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates. Blood, 98, 1616–1618.
12.
DeanJ.M. (1992). Multivariate Pattern Recognition in Chemometrics Illustrated by Case Studies (Brereton, Elsevier, Amsterdam).
13.
FerlayJ., BrayF., PisaniP., and ParkinD.M.(2001) GLOBOCAN 2000. Cancer Incidence, Mortality and Prevalence Worldwide, Cancer Base No. 5 (IARC Press, Lyon).
14.
FleischH. (2002). Development of bisphosphonates. Breast Cancer Res, 4, 30–34.
15.
GholivandK.H., GhazianiF., YaghoubiR., et al. (2010). Design, synthesis and anticholinesterase activity of some new α-aminobisphosphonates. J Enzyme Inhib Med Chem, 25, 25827–25835.
16.
GholivandM.B., KashanianS., PeymanH., et al. (2011). DNA-binding study of anthraquinone derivatives using chemometrics methods. Eur J Med Chem, 46, 2630–2638.
17.
GreenJ.R. (2003). Antitumor effects of bisphosphonates. Cancer, 97, 840–847.
18.
GrutzendlerJ., and MorrisJ.C. (2001). Cholinesterase inhibitors for Alzheimer's disease. Drugs, 61, 41–52.
19.
HirabayashiH., SawamotoT., FujisakiJ., et al. (2002). Dose-dependent pharmacokinetics and disposition of bisphosphonic prodrug of diclofenac based on osteotropic drug delivery system (ODDS). Biopharm Drug Dispos, 23, 307–315.
20.
HoughtonT.J., TanakaK.S.E., KangT., et al. (2008). Linking bisphosphonates to the free amino groups in fluoroquinolones: preparation of osteotropic prodrugs for the prevention of osteomyelitis. J Med Chem, 51, 6955–6969.
21.
JacksonJ.E. (1991). A User's Guide to Principal Components. (Wiley, New York, NY).
22.
JacksonJ.E., and MudholkarG.S. (1979). Control procedures for residuals associated with principal component analysis. Technometrics, 21, 341–349.
23.
JohnsonJ.J., and MukhtarH. (2007). Curcumin for chemoprevention of colon cancer. Cancer Lett, 255, 170–181.
24.
KafarskiP., LejczakB., ForlaniG., et al. (1997). Herbicidal derivatives of aminomethylenebisphosphonic acid. Part III. Structure—activity relationship. Plant Growth Regul, 16, 153–158.
25.
KafarskiP., LejczakandB., and ForlaniG. (2001). Biodegradation of pesticides containing carbon-to-phosphorus bond. ACS Symp Ser, 777, 145–153.
26.
KashanianS., KhodaeiM.M., RoshanfekrH., et al. (2011). DNA binding, DNA cleavage, and cytotoxicity studies of two new copper (II) complexes. DNA Cell Biol, 30, 287–296.
27.
KiranY.B., ReddyC.D., GunasekarD., et al. (2008). Synthesis and anticancer activity of new class of bisphosphonates/phosphanamidates. Eur J Med Chem, 43, 885–892.
28.
KishoreG.M., and ShahD.M. (1988). Amino acid biosynthesis inhibitors as herbicides. Annu Rev Biochem, 57, 627–663.
29.
LattS.A., and WohllebJ.C. (1975). Optical studies of the interaction of 33258 Hoechst with DNA, chromatin, and metaphase chromosomes. Chromosoma, 52, 297–316.
30.
LiQ.S., YangP., WangH.F., et al. (1996). Diorganotin(IV) antitumor agent. (C2H5)2SnCl2 (phen)/nucleotides aqueous and solid-state coordination chemistry and its DNA binding studies. J Inorg Biochem, 64, 181–195.
31.
MakhaevaG.F., AksinenkoA.Y., SokolovV.B., et al. (2009). Synthesis of organophosphates with fluorine-containing leaving groups as serine esterase inhibitors with potential for Alzheimer disease therapeutics. Bioorg Med Chem Lett, 19, 5528–5530.
32.
MartinM.B., SandersJ.M., KendrickH., et al. (2002). Activity of bisphosphonates against Trypanosoma bruceirhodesiense. J Med Chem, 45, 2904–2914.
33.
McKennaC.E., KashemirovB.A., and RozéC.N. (2002). Carbonylbisphosphonate and (diazomethylene)bisphosphonate analogues of AZT 5′-diphosphate. Bioorg Chem, 30, 383–395.
34.
MoriI., IwasakiG., and HayakawaK.J. (1996). Rational design of a new herbicide by inhibition of histidine biosynthesis design and synthesis of inhibitors of imidazole glycerol phosphate dehydratase. Synth Org Chem Jpn 54,514.
35.
NCBI (National Center for Biotechnology Information). Available at: www.ncbi.nlm.nih.gov/genbank
36.
NiY.N., LinD.Q., and KokotS. (2005). Synchronous fluorescence and UV-vis spectrometric study of the competitive interaction of chlorpromazine hydrochloride and Neutral Red with DNA using chemometrics approaches. Talanta, 65, 1295–1302.
ParkinsonJ.A., BarberJ., DouglasK.T., et al. (1990). Minor-groove recognition of the self-complementary duplex d(CGCGAATTCGCG)2 by Hoechst 33258: a high-field NMR study. Biochemistry, 29, 10181–10190.
39.
RodanG.A., and MartinT.J. (2000). Therapeutic approaches to bone diseases. Science, 289, 1508–1514.
40.
SearleM.S., and EmbreyK.J. (1990). Sequence-specific interaction of Hoechst 33258 with the minor groove of an adenine-tract DNA duplex studied in solution by 1H NMR spectroscopy. Nucleic Acids Res, 18, 3753–3762.
41.
SimoniD., GebbiaN., InvidiataF.P., et al. (2008). Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a gammadelta-T lymphocytes-mediated activation mechanism. J Med Chem, 51, 6800–6807.
42.
SongY., WuQ., YangP., et al. (2006). DNA binding and cleavage activity of Ni(II) complex with all-trans retinoic acid. J Inorg Biochem, 100, 1685–1691.
43.
Spatran'10-Quantum Mechanics Program: (PC/x86) 1.1.0v4. (2011). Wavefunction, Inc., USA.
44.
SufenW., TuzhiP., YangC.F. (2002). Electrochemical studies for the interaction of DNA with an irreversible redox compound—Hoechst 33258. Electroanalysis, 14, 1648–1653.
45.
TengM.K., UsmanN, FrederickC.A., et al. (1988). The molecular structure of the complex of Hoechst 33258 and the DNA dodecamer d(CGCGAATTCGCG). Nucleic Acids Res, 16, 2671–2690.
46.
VieillardM.H., MaesJ.M., PenelG., et al. (2008). Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy. Joint Bone Spine, 75, 34–40.
47.
WidlerL., JaeggiK.A., GlattM., et al. (2002). Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). J Med Chem, 45, 3721–3738.
48.
ZekriJ., AhmedN., ColemanR.E., and HancockB.W. (2001). The skeletal metastatic complications of renal cell carcinoma. Int J Oncol, 19, 379–382.
49.
ZhangG., WangL., Zhou, X., et al. (2014). Binding characteristics of sodium saccharin with calf thymus DNA in vitro. J Agric Food Chem, 62, 991–1000.
50.
ZhangY., ZhangG., LiY., et al. (2013). Probing the binding of insecticide permethrin to calf thymus DNA by spectroscopic techniques merging with chemometrics method. J Agric Food Chem, 61, 2638–2647.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
